All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Long-term follow-up of AML patients receiving an autologous telomerase-based dendritic cell vaccine

By Cynthia Umukoro

Share:

May 8, 2017


In an article published in Cancer, Hanna J. Khoury from Emory University School of Medicine, Atlanta, Georgia, and colleagues discussed results from their multicenter, open-label phase II study (NCT00510133), which evaluated the safety, feasibility, and efficacy of Human Telomerase Reverse Transcriptase (hTERT)-expressing Autologous Dendritic Cells (hTERT-DCs) vaccine in adult Acute Myeloid Leukemia (AML) patients.

In total, twenty-one patients (median age = 58 years) with intermediate-risk or high-risk AML either in first or second Complete Remission (CR, n = 19) or had early disease recurrence (n =2) received ≥ 3 doses of hTERT-DC vaccine.

The key results of the study were:

  • Grade ≥ 3 Adverse Events (AEs) occurred in 29% (6/21) of patients who received hTERT-DC treatment
  • One patient receiving hTERT-DC vaccine developed a grade 4 idiopathic thrombocytopenic purpura
  • 58% (11/19) of patients receiving hTERT-DC vaccinations at CR developed positive hTERT T-cell response at ≥ 1 time point after administration
  • hTERT specific T-cell responses significantly targeted peptides with low binding affinity for Human Leukocyte Antigen (HLA) compared to peptides with high affinity for HLA
  • At median follow up of 52 months, 58% of patients in CR (11/19) were free from disease recurrence
  • 57% of the patients in CR who were aged ≥ 60 years (4/7) at the time of administration of hTERT-DC vaccine were free of disease recurrence at a median follow-up of 54 months

The authors concluded by stating that “the generation of hTERT-DCs is feasible and vaccination with hTERT-DCs appears to be safe and may be associated with favorable recurrence-free survival” in high-risk patients with AML.

Abstract

BACKGROUND:

Telomerase activity in leukemic blasts frequently is increased among patients with high-risk acute myeloid leukemia (AML). In the current study, the authors evaluated the feasibility, safety, immunogenicity, and therapeutic potential of human telomerase reverse transcriptase (hTERT)-expressing autologous dendritic cells (hTERT-DCs) in adult patients with AML.

METHODS:

hTERT-DCs were produced from patient-specific leukapheresis, electroporated with an mRNA-encoding hTERT and a lysosomal-targeting sequence, and cryopreserved. A total of 22 patients with a median age of 58 years (range, 30-75 years) with intermediate-risk or high-risk AML in first or second complete remission (CR) were enrolled. hTERT-DCs were generated for 24 patients (73%). A median of 17 intradermal vaccinations (range, 6-32 intradermal vaccinations) containing 1×107 cells were administered as 6 weekly injections followed by 6 biweekly injections. A total of 21 patients (16 in first CR, 3 in second CR, and 2 with early disease recurrence) received hTERT-DCs.

RESULTS:

hTERT-DCs were well tolerated with no severe toxicities reported, with the exception of 1 patient who developed idiopathic thrombocytopenic purpura. Of the 19 patients receiving hTERT-DCs in CR, 11 patients (58%) developed hTERT-specific T-cell responses that primarily were targeted toward hTERT peptides with predicted low human leukocyte antigen (HLA)-binding affinities. With a median follow-up of 52 months, 58% of patients in CR (11 of 19 patients) were free of disease recurrence at the time of their last follow-up visit; 57% of the patients who were aged ≥60 years (4 of 7 patients) also were found to be free of disease recurrence at a median follow-up of 54 months.

CONCLUSIONS:

The generation of hTERT-DCs is feasible and vaccination with hTERT-DCs appears to be safe and may be associated with favorable recurrence-free survival.

References